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Abstract
Introduction: The strategy to Eliminate Yellow Fever Epidemics (EYE) is a global initiative that 
includes all countries with risk of yellow fever (YF) virus transmission. Of these, 40 countries (27 
in Africa and 13 in the Americas) are considered high-risk and targeted for interventions to 
increase coverage of YF vaccine. Even though the World Health Organization (WHO) 
recommends that YF vaccine be given concurrently with the first dose of measles-containing 
vaccine (MCV1) in YF-endemic settings, estimated coverage for MCV1 and YF vaccine have 
varied widely. The objective of this study was to review global data sources to assess discrepancies 
in YF vaccine and MCV1 coverage and identify plausible reasons for these discrepancies.
Methods: We conducted a desk review of data from 34 countries (22 in Africa, 12 in Latin 
America), from 2006 to 2016, with national introduction of YF vaccine and listed as high-risk by 
the EYE strategy. Data reviewed included procured and administered doses, immunization 
schedules, routine coverage estimates and reported vaccine stock-outs. In the 30 countries 
included in the comparitive analysis, differences greater than 3 percentage points between YF 
vaccine and MCV1 coverage were considered meaningful.
Results: In America, there were meaningful differences (7–45%) in coverage of the two vaccines 
in 6 (67%) of the 9 countries. In Africa, there were meaningful differences (4–27%) in coverage of 
the two vaccines in 9 (43%) of the 21 countries. Nine countries (26%) reported MVC1 stock-outs 
while sixteen countries (47%) reported YF vaccine stock-outs for three or more years during 
2006–2016.
Conclusion: In countries reporting significant differences in coverage of the two vaccines, 
differences may be driven by different target populations and vaccine availability. However, these 
were not sufficient to completely explain observed differences. Further follow-up is needed to 
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identify possible reasons for differences in coverage rates in several countries where these could 
not fully be explained.
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1. Introduction
Yellow fever (YF) is a vaccine preventable, viral disease transmitted by infected mosquitoes 
[1]. The clinical spectrum of infection ranges from asymptomatic infection to severe disease 
including jaundice and death [2]. In the early 1990s, 200,000 cases of YF and 30,000 deaths 
were expected globally, with 90% occurring in Africa [3]. Of the more than 1900 YF cases 
and nearly 950 deaths recorded in South America, Peru and Bolivia reported the highest 
incidence of disease [4]. Recent updates from a 2013 modelling study using African data 
sources estimated a burden of 84,000–170,000 severe cases, resulting in 29,000–60,000 
deaths due to YF [5]. The vast majority of cases (>90%) continue to occur in sub-Saharan 
Africa, with countries in the Americas, endemic for YF disease, experiencing seasonal cases. 
Accurately quantifying the burden of disease remains challenging given limitations in 
epidemiological and laboratory surveillance in the affected regions. As specific treatment for 
YF is unavailable, an emphasis is placed on prevention of the disease. Insufficient or 
ineffective control strategies can result in devastating epidemics with high case-fatality rates, 
especially in populations with low pre-existing levels of immunity [6].
The most important means of preventing YF disease is vaccination using a safe and 
affordable vaccine [2]. A single dose of YF vaccine confers life-long protection and provides 
effective immunity to 99% of vaccinated persons within 30 days. Yet, despite an effective, 
live attenuated vaccine, the virus continues to cause major outbreaks [7]. In 1998, the WHO 
Technical Consensus Meeting on Yellow Fever examined reasons for the dramatic 
resurgence of YF outbreaks and concluded that immunization coverage of 80% or more was 
needed to prevent epidemics [8,9]. Key recommendations from the meeting included 
improving YF vaccine coverage through routine immunization and preventive mass 
campaigns, improving detection of cases and laboratory support. The meeting also 
recommended the creation of an emergency stockpile of 1 million YF vaccine doses in 
Africa and South America for reactive campaigns [9].
In 2001, the stockpile was established with 2 million doses and from its creation to 2013, 
more than 65 million doses of vaccine were distributed. By 2014, the emergency stockpile 
contained around 6 million doses [10]. In 2016, large YF outbreaks in Angola and the 
Democratic Republic of the Congo (DRC) created an urgent need for more than 28 million 
doses and repeatedly exhausted the stockpile, hampering efforts to control the epidemics 
through wide scale reactive vaccination campaigns [11]. The multiple and acute vaccine 
shortages underlined gaps in existing preparedness and the need for sustained preventive 
vaccination in at-risk populations [12,13]. In October 2016, WHO’s Strategic Advisory 
Group of Experts (SAGE) on Immunization reviewed existing control tools and outlined a 
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long-term and global strategy to “Eliminate Yellow Fever Epidemics” (EYE) globally by 
2026 [11].
The EYE strategy includes three primary objectives: protect at-risk populations; prevent 
international spread of YF virus; and rapidly contain yellow fever outbreaks. The strategy 
also calls for a new stockpile model: A Revolving Emergency Stockpile. The stockpile will 
be replenished as soon as vaccine becomes available and improve preparedness response 
[11]. The strategy classifies 21 (60%) of 35 at-risk countries in Africa and all 13 YF-
endemic countries in the Americas as high risk for outbreaks of YF and in need of a 3-
pronged vaccination approach (routine childhood immunization, catch-up and preventive 
mass campaigns) to ensure high coverage with YF vaccine in order to achieve and maintain 
high levels of population immunity.
Currently, all 13 countries endemic for, or with regions that are endemic for, YF in the 
Americas have introduced YF vaccine in their routine immunization programs while in 
Africa, 5 endemic countries have yet to introduce the vaccine [8,14]. WHO recommends that 
YF vaccine be given to children at age 9–12 months concurrently with the first dose of 
measles-containing vaccine (MCV1) in YF-endemic settings [3]. While a few countries have 
adopted their own immunization schedule, similar coverage levels for the two vaccines may 
be expected in areas adhering to recommendations for concurrent administration. However, 
discrepancies in estimated routine coverage for YF vaccine and MCV1 have been 
documented by immunization programs. In the African region, estimated MCV1 coverage 
increased from 53% in 2000 to 73% in 2010, to 74% in 2015 and decreased to 72% in 2016 
[15,16]. In the Americas, from 2000 to 2016, MCV1 coverage has remained stable at 92% 
[17]. In contrast, from 2000 to 2016, YF vaccine coverage in childhood immunization 
programs increased from 9% to 45% in Africa and from 24% to 53% in the Americas in 
yellow fever endemic countries [18]. Overall in 2016, population coverage for YF vaccine in 
at-risk countries ranged from 0% in parts of Central and East Africa to nearly 100% in at-
risk districts in Brazil [18].
The objectives of this study were to review and compare estimated routine coverage of YF 
vaccine and MCV1 in Africa and Latin America from 2006 to 2016, to identify whether and 
where discrepancies in coverage occurred, and to explore plausible explanations for the 
observed discrepancies in vaccine coverage.
2. Methods
2.1. Data extraction and collation
Data on immunization coverage – number of administered doses, immunization schedules, 
reported vaccination campaigns, administrative and official government estimated coverage 
– were obtained from official annual reports to the WHO/United Nation Children’s Fund 
(UNICEF) from national immunization program authorities as part of a program 
performance data collection exercise (Table 1). The data collection exercise has been 
previously described [19]. Briefly, using a standardized questionnaire, the Joint Reporting 
Form on Immunization (JRF), WHO and UNICEF collect information from national 
immunization programs on planning, performance, financing and quality indicators [14,19]. 
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Data on routine infant vaccination coverage were obtained from the 2017 revision of the 
WHO and UNICEF estimates of national immunization coverage (WUENIC). WUENIC are 
derived from a country-by-country review of administrative and survey-based coverage data 
[20,21] (Table 1). Descriptive and explanatory texts, included in each country’s final 
WUENIC immunization coverage report, were also reviewed for additional contextual 
factors on program performance as well as actions implemented to address challenges.
Vaccine stock data as well as incidence and duration of reported vaccine stock-outs from 
2006 to 2016 were used as a metric of vaccine availability. For information on vaccine stock, 
country-specific data on shipped doses of YF vaccine for the 11-year review period were 
requested of the UNICEF Supply Division by the department of Immunization, Vaccines and 
Biologicals (IVB) of the WHO. In response, the UNICEF Supply Division provided 
aggregate and country-specific summaries of YF vaccine doses supplied to countries in 
Africa (Table 1). Additionally, data reported by immunization programs on the number of 
procured YF vaccine doses were obtained from UNICEF through the UNICEF Vaccine 
Forecasting Tool [22]. Data on supplied YF vaccine doses were not available for the 
Americas as UNICEF is not the supplier for those countries. Data on vaccine stock-outs 
were also obtained from the official annual reports to WHO through the JRF, which includes 
questions on the frequency and duration of stock-outs at the district and national levels [19] 
(Table 1). Data from 34 countries (22 in Africa, 12 in Latin America) who have introduced 
YF vaccine in their Expanded Program for Immunization (EPI) schedules, had available 
WUENIC data available, and are listed by the EYE strategy as high-risk were reviewed [11].
Reported coverage as well and year-to-year trends in coverage of both vaccines were 
reviewed to characterize consistency of the available data. Reported estimated coverage and 
reported vaccine doses administered were also compared. During reported vaccine stock-
outs, data on the number of vaccine doses administered during the year of stock-out were 
compared to the reported vaccine doses administered in both prior and subsequent years. To 
provide insights into plausible explanations for observed meaningful differences, we 
reviewed recommendations for administration of the vaccines, reported stock-out events, 
years of vaccine stock-outs at the national and district levels and WUENIC country 
summaries. Review efforts focused on vaccine availability and data quality since previous 
literature has noted that immunization coverage rates are a function of the supply-side rather 
than demand[23]. Additionally, previous assessments reports on the implementation of the 
WHO Global Vaccine Action Plan (GVAP) – which aims to improve national immunization 
coverage to at least 90% – have identified poor data quality and use, as well as vaccine 
affordability and supply among the barriers to improving vaccination coverage[24].
2.2. Analytical approach
Multi-year differences in coverage estimates from WUENIC were calculated by averaging 
the differences in coverage of MCV1 and YF vaccine for each year of available data. A 
meaningful difference in vaccination coverage of the two vaccines was defined as an average 
difference greater than 3 percentage points, an arbitrary threshold. Descriptive statistics were 
used to present the data.
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3. Results
3.1. Immunization schedule
Of the countries included in the review, 32 countries (94%) had introduced YF vaccine to at-
risk endemic regions or nationwide by 2006. Equatorial Guinea, while listed as high-risk for 
YF transmission by the EYE strategy, introduced the YF vaccine in 2016 and was omitted 
from this review. In the remaining countries, Guinea-Bissau introduced the vaccine 
nationwide in 2008 while Argentina introduced the vaccine to areas near the border of 
Brazil, Bolivia and Paraguay in 2009 (Tables 2 and 3). During the 2006–2016 review period, 
two countries changed their recommendations for YF vaccine administration from selected 
risk areas to all children: Ecuador in 2009 and Suriname in 2011. In the Americas, both 
measles vaccine and YF vaccine are recommended for administration at 12 months of age to 
all children in 9 (75%) of 12 countries included in the review. In the remaining three (25%) 
countries, MCV1 is also recommended for all children at 12 months while YF vaccine is 
recommended for administration to selected at-risk areas at ages 9 months (Brazil), 15 
months (Peru) and 18 months (Argentina) (Table 2). For the 22 countries included in the 
review from the African region, both MCV1 and YF vaccine are recommended for 
administration at 9 months of age to all children in the country with the exception of Kenya, 
where YF vaccine is recommended to children in at-risk areas (Table 3).
3.2. Vaccination coverage
Differences in estimated coverage of the 2 vaccines in countries without nationwide 
introduction of YF vaccine were omitted given differences in target populations, limiting 
routine coverage data based on WUENIC to 30 countries (88%). In the remaining 9 
countries in the Americas, average coverage of YF vaccine ranged from 42% to 97%, while 
coverage of MCV1 ranged from 87% to 97%. Overall, there were meaningful average 
differences (7–45%) in estimated coverage of the two vaccines in 6 (67%) of the 9 countries 
(Table 4). Two countries changed their recommendations for administration from selected 
at-risk communities to national immunization. Following the change in recommendation for 
administration in Ecuador, the average difference between coverage of the two vaccines 
decreased from 42% to 13%. In Suriname, the average difference between coverage of the 
two vaccines decreased from 45 to 10%. Over the 11-year review period, differences in 
estimated coverage for YF vaccine and MCV1 were less than 3 percentage points in Bolivia, 
Guyana and Trinidad and Tobago. In the 21 African countries included in the analysis, 
average coverage of YF vaccine ranged 29–94%, while coverage of MCV1 ranged from 
44% to 94% across the entire review period. There were meaningful average differences (4–
27%) in estimated coverage for YF vaccine and MCV1 in 9 (43%) of the 21 African 
countries (Table 5).
3.3. Vaccine availability
Across the 34 countries reviewed, none reported stock-outs or vaccine stock data for MCV1 
and YF vaccine for all years. Nine countries overall (26%) reported national-level measles 
vaccine stock-outs and sixteen countries (47%) reported national-level YF vaccine stock-
outs for three or more years during 2006–2016 (Table 6). Of the sixteen countries reporting 
national-level YF vaccine stock-outs, eleven (69%) reported meaningful differences in 
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estimated coverage of the YF vaccine and MCV1. Overall, reporting of stock-out data was 
incomplete across the review period. Benin reported no stock-out for MCV1 across the time 
series and only one stock-out of YFV in 2016. Gambia, Mali and Panama also did not report 
stock-outs for any year.
4. Discussion
This report reviews available routine immunization data over an 11-year period for YF 
vaccine and MCV1 and compares average estimated coverage for the 2 vaccines in 30 (88%) 
of the 34 countries designated as high-risk countries for YF transmission by the global EYE 
strategy and have introduced YF vaccine in their national Expanded Program for 
Immunization (EPI) schedules. There were meaningful differences, defined as greater than 3 
percentage points, between the estimated coverage rates of the two vaccines in 6 countries in 
the Americas and 9 countries in Africa. In countries with meaningful observed differences in 
estimated coverage for YF vaccine and MCV1, plausible explanations for these differences 
include: different recommendations for administration of the vaccines resulting in different 
target populations, vaccine stock-outs and possible gaps in program performance reflected 
by differences in official estimated coverage versus survey results and otherwise unexplained 
factors.
In the Americas, Argentina, Brazil and Panama recommend YF vaccine to endemic, at-risk 
areas. In these countries, YF is limited to certain endemic areas but these geographic areas 
are shifting which may lead to revisions in target populations. Among countries 
recommending YF vaccine for selected risk areas, WHO and UNICEF annualize coverage to 
the total national target population. As such, estimated coverage levels for YF vaccine and 
MCV1 are expected to differ in those countries. In Colombia and Peru, while YF vaccine is 
recommended nationwide, the vaccines are not administered concurrently and differential 
attendance at the visits may be driving the observed gaps in coverage. In addition, countries 
in the Americas also reported 25% more stock-out events of YF vaccine than MCV1. 
However, differences in target population estimates and vaccine stock-outs were not 
sufficient to completely explain observed differences in other countries.
In Africa, Kenya is the only country to recommend YF vaccine sub-nationally thus coverage 
of YF vaccine and MCV1 are expected to differ. Previous reports describe availability of YF 
vaccine as a chronic problem in the region and in this review, African countries reported 
more than twice as many years of YF vaccine stock-outs than measles vaccine stock-outs 
[8]. Furthermore, countries reporting differences in estimated coverage of the two vaccines 
reported 45% more stock-outs of YF vaccine than MCV1 which may contribute to the 
observed differences. Yet, reported stock-outs as a plausible explanatory factor is also 
complex, in part due to poor administrative recording and reporting systems in many 
countries [25]. Reporting of vaccine stock-outs was incomplete, thus, it is unclear whether 
there in fact were no stock-outs in these countries or whether there were stock-outs that went 
unreported to WHO and UNICEF. It is also unclear whether challenges in the recording and 
reporting systems would differentially impact MCV1 and YF vaccine coverage. 
Additionally, while some countries reported declines in administered doses during reported 
vaccine stock-outs, others did not. Given that declines in reported administered doses would 
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be expected during stock-outs, this could be indicative of the availability of buffer stocks or 
gaps in the data quality on availability of immunization program resources (vaccine 
availability and funding).
Further follow up is needed to better understand the causes for stock-outs, challenges in 
reporting and recording systems and to identify possible reasons for differences in coverage 
rates in several countries where these could not fully be explained. Comparisons of total 
procured YF vaccine doses through UNICEF Supply Division with reported target 
population estimates suggest that some countries continue to have challenges with vaccine 
forecasting. Additional work with UNICEF Supply Division and the national immunization 
programs may yield additional valuable information to understand challenges with 
appropriate forecasting of YF vaccine.
The findings of this report are subject to a few limitations. First, numerator and denominator 
biases could be present due to outdated census data and gaps in coverage reporting 
capacities, at district and regional levels, which may result in under or overestimates of 
administrative vaccination coverage. Survey data may suffer from recall bias for multiple-
dose antigens given low levels of home-based vaccination records retention. Second, there 
were missing data across the time series for multiple countries. Furthermore, vaccine stock-
outs and their duration are likely to be under-reported and would underestimate the 
magnitude of the issue. In 2014, SAGE raised the concern about potential under-reporting of 
vaccine availability [24]. In the 2014 assessment report of the GVAP of the 5 priority 
problem areas to address to get GVAP back on track, SAGE noted poor quality data on 
vaccine supply as hindering understanding and corrective action [24].
In its EYE strategy, WHO recommends YF vaccine coverage of 80% or greater in the at-risk 
population to prevent and control outbreaks [8]. The EYE strategy is a comprehensive, 
multi-component partnership and supports high and moderate risk countries in Africa and 
the Americas by strengthening their surveillance and laboratory capacity to prevent, detect 
and respond to yellow fever outbreaks [2]. The strategy also supports the implementation 
and sustainability of large-scale measures (routine immunization, preventive and reactive 
vaccination campaigns) to ensure high coverage with YF vaccine in order to achieve and 
maintain high levels of population immunity [8,25].
While YF vaccine coverage has increased since 1970, an estimated 393.7–472.9 million 
people, or 43–52% of the population within yellow fever risk zones still require vaccination 
to achieve the WHO recommended threshold of 80% coverage [18]. Yellow fever vaccine 
remains to be introduced in the national routine immunization schedule of five of the 27 
high-risk countries in Africa and an additional 12 countries should complete wide-range 
preventive campaigns [11,25]. In the Americas, all 13 countries, considered to be at high-
risk by the EYE strategy, have introduced the vaccine in their routine immunization 
programs and 10 countries have conducted mass preventive campaigns, mostly targeting 
populations living in enzootic areas [11]. However, 11 of the 13 countries should plan catch-
up campaigns targeting unprotected sections of the population [8].
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Reactive campaigns and diversion of global vaccine stocks from preventive use to campaigns 
and routine EPI use contribute to reported YF vaccine stock-outs. The limited supply of YF 
vaccine has been a major hurdle in increasing coverage. Between 2013 and 2015, 15 of the 
34 countries that introduced the YF vaccine in their EPI schedule reported national level 
vaccine stock-out[11]. In the Americas, countries receive about half of their vaccine 
requirement, YF vaccine coverage remains around 70% and has been negatively affected by 
the current global vaccine shortage[11]. To address the increased demand for YF vaccine, 
the global supply is expected to increase to between 162 and 183 million doses in 2026 
[11,25].
In addition, countries across income groups and regions experience regular vaccine stock-
outs that in many cases lead to interruptions in immunization services [26]. Other elements 
that affect all vaccines in use in the routine system such as microplanning, forecasting, 
demographic barriers (ethnic minority status, low educational attainment, economic status), 
low community demand may also be contributing to lower immunization coverage, 
especially when coverage for more than one antigen is noted to be >80% [27]. Other flaws 
in implementing vaccination practices such as healthcare workers hesitancy to open a 10 or 
20 dose vial due to concerns of vaccine wastage or refusal to vaccinate children after 11 
months may contribute to poor childhood immunization coverage [11,28].
The EYE strategy notes that differences between YF vaccine and MCV1 coverage need to 
be monitored and better understood. This review addresses part of that gap by identifying 
that in contrast to initial assumptions, coverage of YF vaccine is not consistently below 
coverage of MCV1. In countries reporting significant differences between the coverage, 
differences may be driven by vaccine stock-outs. This review also highlights that gaps in 
availability of data on immunization program performance remain an issue, as noted in 
previous literature.
Effective interventions to mitigate the frequency of stock-outs and their effects should 
include vaccine forecasting – matching supply and demand of YF vaccine, strengthening 
reporting and recording systems, reducing procurement delays and addressing program 
funding gaps. Moreover, while there has been important progress to improve the gaps in 
yellow fever vaccination coverage in at-risk areas, improved vaccination strategies are 
needed to provide adequate protection against outbreaks. Rather than reactive campaigns, 
incorporating YF vaccine in routine immunization, followed by catch-up campaigns for 
adult populations, is the best strategy to achieve long-term high vaccination coverage 
[29,30].
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Table 4
Estimated average routine coverage for YF vaccine and MCV1 based on WUENIC, 2006 – 2016, Americas, (n 
= 9).
Country/Territory Average YF vaccine coverage (%) Average MCV1 coverage (%) Difference (YF vaccine-MCV1) (%)
Bolivia 89 91 −2
Colombia 85 92 −7
Ecuadora 51 93 −42
Guyana 97 97 0
Paraguay 89 88 −24
Peru 69 91 −23
Surinameb 42 87 −45
Trinidad and Tobago 90 91 0
Venezuela 76 87 −11
Abbreviations: YF = Yellow Fever, MCV1 = first dose of measles-containing vaccine, WUENIC = WHO and UNICEF estimates of national 
immunization coverage.
aCountry changed recommendation for administration from select communities to national administration in 2009. For period following change in 
recommendation, 2010–2016, difference in estimated coverage of YF vaccine and MCV1 was 13 percentage points.
bCountry changed recommendation for administration from select communities to national administration in 2011. For period following change in 
recommendation, 2012–2016, difference in estimate coverage of YF vaccine and MCV1 was 10 percentage points.
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Table 5
Estimated average routine coverage for YF vaccine and MCV1 based on WUENIC, 2006–2016 – Africa, (n = 
21).
Country/Territory Average YF vaccine Coverage 
(%)
Average MCV1 coverage 
(%)
Difference (YF vaccine-
MCV1) (%)
Angola 29 56 −27
Benin 71 70 1
Burkina Faso 84 89 −5
Cameroon 77 78 −1
Central African Republic 52 51 1
Chad 39 44 −5
Congo (the) 69 72 −3
Cote D’Ivoire 58 67 −8
Democratic Republic of Congo (DRC) 62 72 −10
Gabon 66 65 1
Gambia 94 94 0
Ghana 89 90 −1
Guinea 46 50 −4
Guinea-Bissaua 68 77 −7
Liberia 68 71 −4
Mali 66 67 −1
Niger (the) 61 69 −8
Nigeria 45 47 −3
Senegal 82 82 −1
Sierra Leone 76 78 −2
Togo 73 74 −1
Abbreviations: YF = Yellow Fever, MCV1 = first dose of measles-containing vaccine, WUENIC = WHO and UNICEF estimates of national 
immunization coverage.
aWUENIC data available from 2008 onward.
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Table 6
Reported years of national level measles and yellow fever vaccine stock-outs – Africa and the Americas (n = 
34), 2006–2016.
Reported measles stock-out (years) Reported YF vaccine stock-out (years)
Americas
Argentina 2 1
Bolivia 0 4
Brazil 3 1
Colombia 0 2
Ecuador 2 1
Guyana 1 4
Panama 0 0
Paraguay 1 0
Peru 4 4
Suriname 5 3
Trinidad and Tobago 2 2
Venezuela 0 3
Africa
Angola 3 6
Benin 0 1
Burkina Faso 0 3
Cameroon 1 0
Central African Republic (the) 0 1
Chad 0 3
Congo 0 3
Côte d’Ivoire 3 7
Democratic Republic of the Congo (the) 3 6
Gabon 2 1
Gambia 0 0
Ghana 1 2
Guinea 3 1
Guinea-Bissau 3 6
Kenya 0 5
Liberia 0 2
Mali 0 0
Niger (the) 2 4
Nigeria 1 4
Senegal 3 4
Sierra Leone 0 4
Togo 1 0
Abbreviations: YF = Yellow Fever, MCV1 = first dose of measles-containing vaccine.
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